U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07200986) titled 'Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects' on Sept. 23.
Brief Summary: This study is designed to demonstrate PK similarity of the proposed biosimilar test product CT-P52 and the reference product, US-licensed Taltz.
Study Start Date: Sept. 17
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
BIOLOGICAL: Ixekizumab
80 mg (single dose), SC injection via PFS
Recruitment Status: RECRUITING
Sponsor: Celltrion
Published by HT Digital Content Services with permission from Health Daily Digest....